Belgium's Celyad H1 net loss narrows on lower expenses

Overview

• Belgium biotechnology firm's first half 2026 net loss narrowed on reduced expenses

• Company posted no revenue for first half 2026, consistent with prior-year period

• Expense reduction driven by workforce cuts, divestments, and cost controls

Outlook

• Company projects existing cash will fund estimated expenditures into 2027

Result Drivers

• WORKFORCE REDUCTION - Co said lower employee benefit expenses were due to workforce cuts implemented during 2025

• DIVESTMENTS - Co said reduced operating expenses reflected strategic divestments, including disposal of R&D facility and catheter business

• COST CONTROLS - Co said ongoing cost control measures and lower external service costs contributed to reduced operating expenses

Company press release:

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "hold"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Reuters Recommended Reads

• Sept 22 - Celldex shares slip as safety concerns cloud skin drug trial win

• Sept 22 - Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study

• Sept 21 - France's Abivax H1 net loss widens on higher expenses driven by clinical programs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)